Skip to main content

Polaryx Therapeutics, Inc.

PLYX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002075320

No open-market purchases or sales by Polaryx Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $5.83M in total; no superinvestor holds it.

Holders of 5% or more of PLYX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Polaryx Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of PLYX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Mstone Partners Healthcare Ltd13D48.00%22.7M sharesNewFeb 5, 20261 filingFeb 5, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

1 Schedule 13D or 13G filing on Polaryx Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on PLYX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 5, 20264:05 PM ETMstone Partners Healthcare Ltdand 3 others13D48.00%22.7M sharesNewJan 29, 2026SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Polaryx Therapeutics, Inc. shares.

No Form 144 notices for Polaryx Therapeutics, Inc. are on file.